Patent: 6,649,187

Summary for Patent: 6,649,187

Title:	Use of polyalkylamine polymers in controlled release devices
Abstract:	The invention provides a method and device for administering an amine drug, such as [S-(R,S)]-2-[4-[[(4-methyl)piperazin-1-yl]carbonyl]phenoxy]-3,3-diethyl-N-[1-(3,4-methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide), in a sustained release dosage form. The invention includes a pharmaceutical composition and dosage form containing a polyalkylamine polymer and an amine drug. The polyalkylamine polymer is a hydrogel that forms hydrated particles when exposed to an aqueous environment. When mixed with the amine drug in the core of a coated tablet, the polyalkylamine polymer controls the release of the amine drug into an aqueous environment of use. The hydrated particles of the polymer together with the amine drug are released from the tablet core through plural apertures in the surrounding coat.
Inventor(s):	Munir A. Hussain, Arnold J. Repta
Assignee:	Bristol Myers Squibb Pharma Co
Application Number:	US10/074,385
Patent Claims:	see list of patent claims

Details for Patent 6,649,187

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Aimmune Therapeutics, Inc.	ZENPEP	pancrelipase	Capsule, Delayed Release	022210	27-Aug-09	6,649,187	2022-02-12
Zenpep, Llc	ZENPEP	pancrelipase	Capsule, Delayed Release	022210	August 27, 2009	6,649,187	2022-02-12
Aimmune Therapeutics, Inc.	ZENPEP	pancrelipase	Capsule, Delayed Release	022210	15-Jun-11	6,649,187	2022-02-12
Zenpep, Llc	ZENPEP	pancrelipase	Capsule, Delayed Release	022210	June 15, 2011	6,649,187	2022-02-12
Aimmune Therapeutics, Inc.	ZENPEP	pancrelipase	Capsule, Delayed Release	022210	13-Jul-11	6,649,187	2022-02-12
Zenpep, Llc	ZENPEP	pancrelipase	Capsule, Delayed Release	022210	July 13, 2011	6,649,187	2022-02-12
Aimmune Therapeutics, Inc.	ZENPEP	pancrelipase	Capsule, Delayed Release	022210	25-Mar-14	6,649,187	2022-02-12